{
    "clinical_study": {
        "@rank": "18599", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (alternative medicine procedure)", 
                "arm_group_type": "Experimental", 
                "description": "Patients undergo electroacupuncture therapy to specific acupuncture points on the arms and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total)."
            }, 
            {
                "arm_group_label": "Arm II (alternative medicine procedure)", 
                "arm_group_type": "Sham Comparator", 
                "description": "Patients undergo electroacupuncture therapy to sham points on the arms and legs as in arm I."
            }
        ], 
        "brief_summary": {
            "textblock": "RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in\n      patients treated with chemotherapy.\n\n      PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture\n      in treating delayed nausea and vomiting in patients who are receiving chemotherapy for newly\n      diagnosed childhood sarcoma, neuroblastoma, nasopharyngeal cancer, germ cell tumors, or\n      Hodgkin lymphoma."
        }, 
        "brief_title": "Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma", 
        "completion_date": {
            "#text": "January 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Brain Tumors", 
            "Central Nervous System Tumors", 
            "Childhood Germ Cell Tumor", 
            "Extragonadal Germ Cell Tumor", 
            "Head and Neck Cancer", 
            "Lymphoma", 
            "Nausea", 
            "Vomiting", 
            "Neuroblastoma", 
            "Ovarian Cancer", 
            "Sarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Head and Neck Neoplasms", 
                "Hodgkin Disease", 
                "Lymphoma", 
                "Nausea", 
                "Nervous System Neoplasms", 
                "Neuroblastoma", 
                "Ovarian Neoplasms", 
                "Vomiting", 
                "Central Nervous System Neoplasms", 
                "Neoplasms, Germ Cell and Embryonal", 
                "Neuroectodermal Tumors, Primitive, Peripheral", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      Primary\n\n        -  Determine the efficacy of electroacupuncture, in terms of reducing acute and delayed\n           chemotherapy-induced nausea, in patients with newly diagnosed pediatric sarcoma,\n           neuroblastoma, nasopharyngeal carcinoma, or germ cell tumors.\n\n      Secondary\n\n        -  Determine the efficacy of this therapy, in terms of reducing delayed\n           chemotherapy-induced emesis, in these patients.\n\n        -  Determine the efficacy of this therapy, in terms of altering salivary cortisol levels\n           and fasting serum glucose and insulin levels as stress parameters, in these patients.\n\n        -  Determine the efficacy of this therapy, in terms of improving the quality of life, in\n           these patients.\n\n        -  Determine the efficacy of this therapy, in terms of reducing acute nausea and emesis,\n           in these patients.\n\n      OUTLINE: This is a multicenter, randomized, double-blind study. Patients are stratified\n      according to planned treatment with cisplatin-based chemotherapy (yes vs no) and gender.\n      Patients are randomized to 1 of 2 arms.\n\n        -  Arm I: Patients undergo electroacupuncture to specific acupuncture points on the arms\n           and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7\n           during week 1 of chemotherapy course 1 (9 acupuncture treatments total).\n\n        -  Arm II: Patients undergo electroacupuncture to sham points on the arms and legs as in\n           arm I.\n\n      Quality of life is assessed at baseline, on days 1 and 8 of each treatment course, and then\n      after completion of the study.\n\n      PROJECTED ACCRUAL: A total of 65 patients (approximately 32 per arm) will be accrued for\n      this study within 2.5-3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Newly diagnosed malignancy of 1 of the following types:\n\n               -  Pediatric sarcoma\n\n               -  Neuroblastoma\n\n               -  Nasopharyngeal carcinoma\n\n               -  Germ cell tumor\n\n               -  Hodgkin lymphoma\n\n          -  Meets 1 of the following criteria:\n\n               -  Eligible for Children's Oncology Group (COG) protocol for sarcoma,\n                  neuroblastoma, or germ cell tumor\n\n               -  Eligible for NCI Pediatric Oncology Branch (POB) protocol for sarcoma\n\n               -  Following COG-approved standard treatment regimen for sarcoma, neuroblastoma,\n                  nasopharyngeal carcinoma, or germ cell tumor\n\n               -  Enrolled on the POB natural history protocol 98-C-0037\n\n          -  Planned treatment, according to COG or POB protocols, that includes a cisplatin-\n             and/or doxorubicin-containing regimen for sarcoma, neuroblastoma, nasopharyngeal\n             carcinoma, germ cell tumor, or Hodgkin lymphoma OR either a\n             cyclophosphamide/ifosfamide-doxorubicin-containing or\n             cyclophosphamide/dactinomycin-containing regimen for rhabdomyosarcoma\n\n          -  No clinical or radiographic signs of spinal cord compression\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  5 to 35\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Platelet count greater than 50,000/mm^3 (transfusion independent)\n\n          -  No clotting disorders, including hemophilia\n\n        Hepatic:\n\n          -  PT and PTT normal (within 10% of institution's upper limit of normal)\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  Not pregnant\n\n          -  No casting of 1 or more extremities\n\n          -  No other condition that would preclude access to acupuncture points\n\n          -  No cognitive impairment\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  No prior systemic chemotherapy\n\n        Endocrine therapy:\n\n          -  More than 4 weeks since prior glucocorticoid therapy\n\n          -  No concurrent glucocorticoid therapy\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No prior acupuncture\n\n          -  No concurrent anticoagulants"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 8, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": [
                "NCT00034411", 
                "NCT00034996"
            ], 
            "nct_id": "NCT00040911", 
            "org_study_id": "ACCL04C2", 
            "secondary_id": [
                "NCCAM-02-AT-0172", 
                "NCI-02-AT-0172", 
                "COG-ACCL04C2", 
                "CDR0000069419"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (alternative medicine procedure)", 
                "intervention_name": "electroacupuncture therapy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Arm II (alternative medicine procedure)", 
                "description": "Undergo electroacupuncture therapy to sham points", 
                "intervention_name": "sham intervention", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Arm I (alternative medicine procedure)", 
                    "Arm II (alternative medicine procedure)"
                ], 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "nausea and vomiting", 
            "localized osteosarcoma", 
            "metastatic osteosarcoma", 
            "nonmetastatic childhood soft tissue sarcoma", 
            "metastatic childhood soft tissue sarcoma", 
            "previously untreated childhood rhabdomyosarcoma", 
            "localized Ewing sarcoma/peripheral primitive neuroectodermal tumor", 
            "metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor", 
            "childhood teratoma", 
            "childhood extragonadal germ cell tumor", 
            "childhood malignant testicular germ cell tumor", 
            "childhood malignant ovarian germ cell tumor", 
            "childhood central nervous system germ cell tumor", 
            "localized resectable neuroblastoma", 
            "localized unresectable neuroblastoma", 
            "disseminated neuroblastoma", 
            "regional neuroblastoma", 
            "stage 4S neuroblastoma", 
            "stage I lymphoepithelioma of the nasopharynx", 
            "stage I squamous cell carcinoma of the nasopharynx", 
            "stage II lymphoepithelioma of the nasopharynx", 
            "stage II squamous cell carcinoma of the nasopharynx", 
            "stage III lymphoepithelioma of the nasopharynx", 
            "stage III squamous cell carcinoma of the nasopharynx", 
            "stage IV lymphoepithelioma of the nasopharynx", 
            "stage IV squamous cell carcinoma of the nasopharynx", 
            "stage I adult Hodgkin lymphoma", 
            "stage I childhood Hodgkin lymphoma", 
            "stage II adult Hodgkin lymphoma", 
            "stage II childhood Hodgkin lymphoma", 
            "stage III adult Hodgkin lymphoma", 
            "stage III childhood Hodgkin lymphoma", 
            "stage IV adult Hodgkin lymphoma", 
            "stage IV childhood Hodgkin lymphoma"
        ], 
        "lastchanged_date": "May 29, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/NCCAM-02-AT-0172"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892-1182"
                }, 
                "name": "Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Study Of Electroacupuncture Treatment For Delayed Chemotherapy-Induced Nausea And Vomiting In Patients With Pediatric Solid Tumors", 
        "overall_official": {
            "affiliation": "Herbert Irving Comprehensive Cancer Center", 
            "last_name": "Kara Kelly, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A two-sample t-test will be used. In the event the data are not normally distributed in one or both arms, a Wilcoxon rank sum test will be used.", 
            "measure": "Delayed nausea by Marrow Assessment of Nausea and Emesis at  1, 3, and 6 weeks after study completion", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "removed_countries": {
            "country": "Canada"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040911"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Quality of life by QLQ C-30 at  1, 3, and 6 weeks after study completion", 
                "safety_issue": "No", 
                "time_frame": "Day 8"
            }, 
            {
                "description": "It is anticipated that Cochran-Armitage trend tests will be used to compare the results between randomized groups.", 
                "measure": "Pain by Brief Pain Inventory at  1, 3, and 6 weeks after study completion", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Children's Oncology Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Center for Complementary and Alternative Medicine (NCCAM)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "Children's Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2005", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }, 
    "geocoordinates": {
        "Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office": "38.985 -77.095"
    }
}